Table 3.
Severity, management and timing of adverse events following vaccination with Janssen COVID-19 vaccine among the participants, Ayder comprehensive specialized hospital, Mekelle, Tigray, Northern Ethiopia, 2022 (n = 442).
| Characteristic | Frequency (%) | 95% CI |
|---|---|---|
| Previously vaccinated with AstraZeneca | 266 (60.2) | 55.5, 64.6 |
| Had adverse events following AstraZeneca | 132 (49.6) | 43.6, 55.6 |
| Perceived severity of adverse event (Janssen vs AstraZeneca) | ||
| More severe | 67 (50.8) | 42.2, 59.2 |
| Similar | 37 (28.0) | 21.0, 36.4 |
| Less severe | 28 (21.2) | 15.0, 29.1 |
| Perceived adverse event severity | ||
| Very mild | 61 (16.6) | 13.1, 20.7 |
| Mild | 137 (37.2) | 32.4, 42.3 |
| Moderate | 126 (34.2) | 29.5, 39.2 |
| Severe | 37 (10.1) | 7.3, 13.6 |
| Very severe* | 7 (1.9) | 0.9, 3.9 |
| Side effect required treatment | 147 (40.0) | 35.0, 45.0 |
| Type of treatment required | ||
| Home based treatment | 44 (30.0) | 23.0, 37.9 |
| Over the counter medication | 95 (64.6) | 56.5, 72.0 |
| Consultation with a healthcare professional | 5 (3.4) | 1.4, 8.0 |
| Visit to the emergency rooma | 3(2.0) | 0.6, 6.2 |
| Onset of symptoms after vaccination [median (IQR)], in hours | 6 (9) | 7.6, 9.3 |
| Duration of symptoms [median (IQR)], in hours | 24 (30) | 32.6, 40.8 |
*Four had urticaria, two developed anaphylactic reaction while one reported transient arm weakness.
aTwo with anaphylactic reaction and one with urticaria.
IQR interquartile range.